United in Fight Against Prostate Cancer Registry (UFO): Treatment Patterns and Quality of Life from a Large, Multi-Center, Longitudinal Cohort Study in Asia
R. Kanesvaran,H. Uemura,D. Ye,E. Chiong,B. Lojanapiwat,Y-S. Pu,S. Kumar Rawal,A. H. A. Razack,H. Zeng,B. H. Chung,Y-S. Tsai,M. Y. Noor Ashani,Y. Liu,M. Asinas-Tan,W. Liu,G. K. M. Low,M. van Kooten Losio
DOI: https://doi.org/10.1093/annonc/mdy434
IF: 51.769
2018-01-01
Annals of Oncology
Abstract:Background: The prostate cancer (PC) registry (UFO) has been established with the aim of providing a comprehensive picture of PC diagnosis, prognosis, treatment and outcome in Asia. The registry will also collect patient-reported treatment outcomes and underlying reasons for clinical decision-making. Methods: This is a large multi-national, observational registry of PC patients presenting to tertiary care hospitals in China, India, Japan, Malaysia, Singapore, South Korea, Taiwan and Thailand. Patients with existing or newly diagnosed high-risk localized PC (HRL), non-metastatic biochemically recurrent PC (M0), or metastatic PC (M1), are being consecutively enrolled and followed for up to 5 years. Quality of life is assessed using EQ5D and FACT-P. The first interim analysis includes 2,063 patients enrolled from study start (15 Sept 2015) until 17 May 2017. Results: At diagnosis, 56% of all patients had extra-capsular extension of their tumor, 28% had regional lymph node metastasis and 53% had distant metastases. Treatment of M1 patients was mainly with combined androgen blockade (58%) or androgen deprivation therapy (32%) (Table). At enrolment, 97% of M1 patients had ECOG 0-2, 83% reported no or slight pain or discomfort, >84% reported no or slight problems with mobility, dressing or washing, or usual activities, and 92% reported no or slight anxiety and depression. Mean EQ5D visual analogue score was 74.6-79.6 across cohorts. Of 346 M1 patients who reported use of pain medications, 73% used simple analgesics and 36% used weak opioid analgesics for symptom control. Conclusions: More than 50% of patients diagnosed with PC in our study presented with advanced disease. Few patients reported pain, significant functional impairment or use of strong analgesics.Table212O Characteristics of patients with prostate cancerCharacteristicHRL N = 357M0 N = 378M1 N = 1328mHSPC N = 1038mCRPC N = 290TMN stage at PC diagnosis%%%%T3a83.234.458.146.5Tx0.67.417.224.5N070.984.432.128.6N117.69.838.134.1Nx11.54.829.937.2M093.692.611.219.0M10084.575.9Mx6.47.44.215.2Treatment pattern at registry enrolmentCombined androgen blockade41.731.757.062.8Androgen deprivation therapy*36.437.331.134.5Anti-androgen monotherapy3.62.16.21.7Other10.924.61.00.3No prior hormonal treatment received**5.03.74.60.7Missing2.20.50.10.0mHSPC = hormone-sensitive prostate cancer, mCRPC = castration-resistant prostate cancer. *Either orchiectomy of LHRH agonist. ** patients may have received treatment after registry enrolment Open table in a new tab mHSPC = hormone-sensitive prostate cancer, mCRPC = castration-resistant prostate cancer. *Either orchiectomy of LHRH agonist. ** patients may have received treatment after registry enrolment Editorial acknowledgement: Writing assistance was provided by Joanne Wolter, Independent on behalf of Janssen. Clinical trial identification: NCT02546908. Registry Identifier: NOPRODPCR4001. Legal entity responsible for the study: Janssen Research & Development. Funding: Janssen Research & Development. Disclosure: R. Kanesvaran: Grants, personal fees: J&J, outside the submitted work. H. Uemura: Grants: Janssen, Astellas, Takeda, AstraZeneca; Personal fees: AstraZeneca, Astellas, Sanofi; Other from Sanofi, outside the submitted work. E. Chiong: Institutional grants: Janssen during the conduct of the study; Honoraria, conference support: Janssen outside the submitted work. Y. Liu: Employee: Janssen Research and Development, LLC; Holds stock: J&J M. Asinas-Tan: Employee: Johnson and Johnson Pte Ltd. W. Liu: Employee: Johnson & Johnson (China) Investment Ltd.,. G.K.M. Low: Employee: Janssen Asia Pacific, Medical affairs; Holds stock: J&J. M. van Kooten Losio: Employee: Johnson and Johnson Pte Ltd; Holds stock: J&J. All other authors have declared no conflicts of interest.